PCAS - CHBD IN CHINA & CPHI IN JAPAN

Longjumeau, April 8th, 2014

CHBD IN CHINA

On February 28th of 2014, in the framework of its strategic development in Asia and particularly in China, PCAS has joined the CHDB "China Healthcare Business Development" Alliance and has attended a CHBD Seminar in Guangzhou, Guangdong province, South-East China.
The CHBD Alliance is gathering both Chinese and Overseas Pharmaceutical & Healthcare related companies, to enhance exchanges, promote collaboration and develop new opportunities. The CHBD Alliance was created to become the greatest Pharmaceutical & Healthcare Industry business development agency in China. As a new member of the CHBD Alliance, PCAS is now joining Chinese leaders like China Resources Sanjiu Medical & Pharmaceutical and foreign leaders like Teva Pharmaceutical Industries.
PCAS Group is consequently reinforcing its strategic position in China and laying the foundations which will make of French Group an unavoidable partner of the Chinese Pharmaceutical Industry in a close future.

CPHI IN JAPAN

From April 9th to 11th of 2014, PCAS will attend the CPHI Japan exhibition, in Tokyo.
For the occasion, Mr. Moretti, PCAS Group's Chairman will encounter Mr. Watanabe, President of Watanabe Chemical Co. Ltd., to sign a Representative Agreement settling Watanabe Chemical Co. Ltd. as our Agent in Japan for our ophthalmic related APIs.
This is a very important step for both PCAS and Watanabe, formalizing several years of successful collaboration and our promising future long-term partnership."
Don't miss a chance to meet us: PCAS will have a dedicated booth during CPHI Japan, J-39 stand!

Next date: 2014 Shareholder's Meeting,

at 10 a.m. on Wednesday, April 23, 2014 in Longjumeau

About PCAS:

Founded in 1962, PCAS is an international fine and specialty chemicals group (165 million € net sales in 2013) that shares an ambition for excellence with its customers, which primarily include market-leading international groups. PCAS designs and delivers the best industrial solutions for its customers' specific expectations. These various expectations all share a common demand for safety, quality, competitiveness, innovation and sustainability. PCAS also develops ranges of

proprietary products based on intellectual property.

Financial reporting: Vincent Touraille - Eric Moissenot | W +33 (0)1 69 09 77 85 | www.pcas.com

distributed by